ÁñÁ«ÊÓƵ

This Viewpoint examines whether overdiagnosis rather than underdiagnosis may now be the dominant form of myocardial infarction misdiagnosis.

This genetic association study investigates if mendelian randomization can identify associations between circulating cardiovascular disease–related proteins and hypertensive disorders of pregnancy.

This randomized trial assesses the effect of 12 months of atorvastatin vs placebo on development of cardiac dysfunction among patients with lymphoma undergoing anthracycline-based chemotherapy.

This post hoc analysis of a randomized clinical trial evaluates the safety and efficacy of empagliflozin in patients with heart failure and preserved ejection fraction who are taking diuretics.

This JAMA Insights Clinical Update discusses various clinical aspects of lipoprotein(a), including association with cardiovascular disease risk, measurement, guideline recommendations, and emerging therapies.

This narrative review summarizes the epidemiology, pathophysiology, diagnosis, management, and prognosis of heart failure with reduced ejection fraction.

This secondary analysis of a randomized clinical trial examines medical therapy and reasons why an intervention did not work for patients with heart failure in the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment.

This cohort study uses UK Biobank data to compare the development of cardiovascular diseases (CVD) and cardiovascular risk factors in women with premature (before age 40 years) vs nonpremature natural and surgical menopause.

This exploratory cohort study of patients with heart failure with reduced ejection fraction (HFrEF) assesses the association between change in N-terminal pro–B-type natriuretic peptide (NT-proBNP) after starting sacubitril-valsartan and changes in left ventricular ejection fraction, diastolic volume, and other measures of physiologic cardiac function.

This narrative review describes the association of cardiac troponin concentration with myocardial injury in the absence of myocardial infarction and reviews the epidemiology, differential diagnosis, diagnostic evaluation, and management of myocardial injury.

This cross-sectional study investigates whether the introduction of a new, stratified payment adjustment method is associated with an alteration in the distribution of penalties among hospitals included in the Hospital Readmissions Reduction Program.

This cohort study explores whether patients with myocardial injury are being misclassified as having type 2 myocardial infarction and if there are implications for 30-day readmission and mortality rates.

This Viewpoint reviews what is known about myocardial infarction (MI) caused by oxygen supply-and-demand mismatch (type 2 MI) and differences from MI caused by coronary artery disease, as well as proposes areas for further investigation to identify optimal management strategies.

This narrative review provides an overview of the epidemiology, pathogenesis, diagnosis, prevention, and treatment of left ventricular thrombus after acute myocardial infarction and offers guidance regarding a practical antithrombotic approach in this setting.

This longitudinal multicohort study evaluates the associations of 12 cardiovascular biomarkers with the development of heart failure with preserved ejection fraction vs heart failure with reduced ejection fraction.

This randomized clinical trial investigates whether reducing natriuretic peptide levels by titrating medication to reach the target of less than 1000 pg/mL in patients with heart failure and reduced ejection fraction improves clinical outcomes.